Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia.
We measured serum aluminum concentrations in 104 haemodialysis patients from 3 centres in Hong Kong. We found that the 52 patients dialyzed in unit A had much higher mean aluminium levels (100 micrograms/L) than those from the other two units (61 and 39 micrograms/L respectively). In unit A, where water treatment by reverse osmosis had been introduced only recently, 30.8% of patients had fractures/looser zones, 46.2% had rugger-jersey spine and 28.8% had skeletal erosions. When these patients were divided into two groups according to whether their serum aluminium concentration was below or above 100 micrograms/l, the latter patients had significantly lower alkaline phosphatase, serum phosphate, and higher total prescribed dose of aluminium hydroxide. It was concluded that both dialysate aluminium and oral aluminium intake seemed to have contributed to the high incidence of osteomalacic fractures among Unit A patients. In eight of these patients serum aluminium increased by more than 150 micrograms/L after four weeks of receiving 1.5 g desferrioxamine twice weekly. Serial X-rays showed that the mean time after dialysis for the appearance of fractures/Looser zones was 72 months. Three patients developed fractures/Looser zones after successful renal transplantation; and it was postulated that the prompt excretion of aluminium permitted increased osteoclastic activity, resulting in fractures in these patients.
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
M K
MK
Chan
Z
Z
Varghese
M K
MK
Li
W S
WS
Wong
C S
CS
Li
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D000535:Aluminum / Q000097:blood* / Q000633:toxicity; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology; D006723:Hong Kong; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010018:Osteomalacia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D010710:Phosphates / Q000097:blood; D011859:Radiography; D006435:Renal Dialysis / Q000009:adverse effects; D013054:Spectrophotometry, Atomic
D010710:Phosphates; D000536:Aluminum Hydroxide; D000535:Aluminum; D000469:Alkaline Phosphatase; D003676:Deferoxamine